SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Interest Income

Income earned on cash, deposits, and investments held by the company.

SIGA Technologies, Inc.NASDAQ: SIGA

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income dips below year-ago levels

Q1 FY2026 interest income of $1.28M fell 24.2% year over year, behind the +161.5% change in trailing-twelve-month interest income. Sequentially, it fell 16.8% from the prior quarter.

Context

  • Interest income amounted to 7.1% of revenue in FY2025, up 7.1 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -24.2% toward the trailing-twelve-month pace of +161.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.28M-16.8% QoQ
Last fiscal yearDec 2025
$6.68M— YoY
LTMMar 2026
$4.41M+161.5% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.2%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
6.68M USD
Year-over-year change
—

Interest Income vs competitors

How SIGA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +161.5% is the highest of 8, against a peer median of -2.6%.
  • Interest income amounts to 4.7% of revenue for SIGA, versus a peer median of 0.4%.
SIGA Competitors
Interest Income for SIGA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$16.48M USD+18.9%+93.8%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$5.74M USD-2.6%+45.8%16.2%
SNDLSNDL Inc.LTM Mar 2026CA$5.03M CAD-77.6%-23.0%0.5%
SIGASIGA Technologies, Inc.LTM Mar 2026$4.41M USD+161.5%—4.7%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$4.3M USD+105.5%+75.2%1.4%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$1.7M USD+76.9%—0.3%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$1.1M USD——0.3%
DRIODarioHealth Corp.LTM Mar 2026$814K USD-19.8%+23.1%3.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding SIGA) —-2.6%+45.8%0.4%

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue133.67M110.78M139.92M138.72M94.6M
Cost of Revenue16.6M10.43M17.83M31.29M29.7M
Gross Profit117.07M100.34M122.09M107.43M64.87M
Gross Margin87.6%90.6%87.3%77.4%68.6%
Research & Development9.94M22.53M16.43M12.31M6.53M
Selling, General & Admin18.03M35.12M22.04M25.14M3.13M
Operating Expenses27.98M57.64M38.47M37.45M41.17M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
EBITDA89.83M44.65M88.31M76.61M30.96M
EBITDA Margin67.2%40.3%63.1%55.2%32.7%
Operating Income89.09M42.7M83.62M69.98M23.7M
Operating Margin66.7%38.5%59.8%50.4%25.1%
Interest Income00006.68M
Interest Expense00000
Other Income / Expenses218.94K1.43M4.16M6.09M6.7M
Income Before Tax89.31M44.13M87.78M76.07M30.4M
Pre-Tax Margin66.8%39.8%62.7%54.8%32.1%
Income Tax Expense19.86M10.23M19.71M16.86M7.1M
Net Income69.45M33.9M68.07M59.21M23.3M
Net Margin52.0%30.6%48.6%42.7%24.6%
EPS (Basic)0.920.460.950.830.33
EPS (Diluted)0.910.460.950.830.33
Weighted Avg Shares75.32M72.93M71.36M71.25M71.6M
Weighted Avg Shares (Diluted)76.4M73.55M71.68M71.77M71.6M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.